Complement Component 5 (C5) Deficiency Improves Cognitive Outcome After Traumatic Brain Injury and Enhances Treatment Effects of Complement Inhibitors C1-Inh and CR2-Crry in a Mouse Model.
C1-Inh
C5 deficiency
CR2-Crry
PMX205
complement system
traumatic brain injury
Journal
Neurotrauma reports
ISSN: 2689-288X
Titre abrégé: Neurotrauma Rep
Pays: United States
ID NLM: 101773091
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
A potent effector of innate immunity, the complement system contributes significantly to the pathophysiology of traumatic brain injury (TBI). This study investigated the role of the complement cascade in neurobehavioral outcomes and neuropathology after TBI. Agents acting at different levels of the complement system, including 1) C1 esterase inhibitor (C1-Inh), 2) CR2-Crry, an inhibitor of all pathways acting at C3, and 3) the selective C5aR1 antagonist, PMX205, were administered at 1 h post-TBI. Their effects were evaluated on motor function using the rotarod apparatus, cognitive function using the active place avoidance (APA) task, and brain lesion size at a chronic stage after controlled cortical impact injury in C5-sufficient (C5
Identifiants
pubmed: 37908321
doi: 10.1089/neur.2023.0024
pii: 10.1089/neur.2023.0024
pmc: PMC10615070
doi:
Types de publication
Journal Article
Langues
eng
Pagination
663-681Informations de copyright
© Min Chen et al., 2023; Published by Mary Ann Liebert, Inc.
Déclaration de conflit d'intérêts
Trent M. Woodruff is an inventor on patents pertaining to complement inhibitors for neurological diseases. He has consulted for Alsonex Pty Ltd (who are commercially developing PMX205) and has received honorarium from Alexion Pharmaceuticals for participation in industry conferences and workshops. He holds no stocks, shares, or other financial interests in either company.
Références
Acta Neuropathol Commun. 2021 Jul 19;9(1):126
pubmed: 34281628
Clin Exp Emerg Med. 2020 Jun;7(2):87-94
pubmed: 32635699
J Clin Invest. 2003 Jun;111(12):1875-85
pubmed: 12813023
Crit Care Med. 2009 Feb;37(2):659-65
pubmed: 19114897
Mol Immunol. 2019 Oct;114:341-352
pubmed: 31446305
Br J Pharmacol. 2017 Apr;174(8):689-699
pubmed: 28128456
Sci Rep. 2018 May 9;8(1):7339
pubmed: 29743575
Brain Res Mol Brain Res. 1997 Oct 15;50(1-2):205-12
pubmed: 9406936
Drug Deliv. 2014 Jun;21(4):302-6
pubmed: 24215253
Front Cell Neurosci. 2014 Sep 09;8:269
pubmed: 25249935
J Neuroimmunol. 2004 Oct;155(1-2):55-63
pubmed: 15342196
PLoS One. 2013 May 14;8(5):e64078
pubmed: 23691153
J Neurotrauma. 2020 Mar 1;37(5):692-705
pubmed: 32000582
Mol Biotechnol. 2001 Jun;18(2):135-48
pubmed: 11471455
Exp Anim. 2015;64(3):261-8
pubmed: 25765875
Mol Immunol. 2008 Oct;45(16):4057-63
pubmed: 18674818
Cell. 2020 Mar 5;180(5):833-846.e16
pubmed: 32142677
Methods Mol Biol. 2000;150:229-47
pubmed: 10857115
Front Neural Circuits. 2021 Apr 28;15:634533
pubmed: 33994956
Front Immunol. 2016 Dec 05;7:556
pubmed: 27994591
Biochem Pharmacol. 2020 Oct;180:114156
pubmed: 32682759
J Neurotrauma. 2018 Jan 15;35(2):226-240
pubmed: 28816089
Sci Rep. 2017 Feb 16;7:42714
pubmed: 28205538
J Neurosci. 2018 Mar 7;38(10):2519-2532
pubmed: 29437855
J Neurotrauma. 2001 Dec;18(12):1295-311
pubmed: 11780861
J Neurosci. 2021 Feb 24;41(8):1830-1843
pubmed: 33446516
J Neuroimmunol. 2014 Nov 15;276(1-2):213-8
pubmed: 25262158
ACS Omega. 2020 Jan 30;5(5):2345-2354
pubmed: 32064396
Nature. 1979 Nov 8;282(5735):207-8
pubmed: 492335
J Neuroinflammation. 2018 Jan 22;15(1):24
pubmed: 29357880
Ther Adv Hematol. 2019 Sep 10;10:2040620719874728
pubmed: 31534662
J Neurotrauma. 2017 Jun 15;34(12):2075-2085
pubmed: 28173736
J Neuroinflammation. 2020 Nov 25;17(1):354
pubmed: 33239010
J Clin Invest. 2005 Sep;115(9):2444-53
pubmed: 16127466
Acta Neuropathol Commun. 2021 Apr 20;9(1):72
pubmed: 33879257